Loading
Alzheimer's Disease / Alzheimer Disease / Transcranial Magnetic Stimulation Sham · Phase 1/2 Trial
ClinicalTrials.gov · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registry record for an actively recruiting Phase 1/2 trial examining whether large-coil rTMS targeting the precuneus is feasible, tolerable, and potentially efficacious for memory in mild cognitive impairment and mild-to-moderate Alzheimer's disease. No results are reported in this registry record. The study is designed to answer mechanistic and safety questions before efficacy claims can be made.
Phase 1/2, Interventional, Randomized, Parallel, Quadruple masking, Other purpose. Alzheimer&Amp;Amp;#39;s Disease, Alzheimer Disease, Dementia Alzheimer Type, Mild Alzheimer&Amp;Amp;#39;s Disease, Moderate Alzheimer&Amp;Amp;#39;s Disease, Al…; age from 55 Years; to 100 Years. Intervention: Open-Label Active deep rTMS (First Study Stage); Randomized Active deep precuneus rTMS. Compared with: Randomized Sham deep precuneus rTMS — Sham Comparator. n = 54. 1 site: United States.
This is a registry record for an actively recruiting Phase 1/2 trial examining whether large-coil rTMS targeting the precuneus is feasible, tolerable, and potentially efficacious for memory in mild cognitive impairment and mild-to-moderate Alzheimer's disease. No results are reported in this registry record. The study is designed to answer mechanistic and safety questions before efficacy claims can be made.
Primary outcome is completion rate (feasibility/tolerability), not cognitive efficacy
Clinicians should note this trial is not yet reporting outcomes and is still enrolling. Once results are available, feasibility and tolerability data will inform whether larger efficacy trials of deep rTMS targeting the precuneus are warranted in Alzheimer's disease.
This is a Phase 1/2 feasibility and tolerability trial still recruiting, with no results posted; it addresses whether deep rTMS of the precuneus is safe and tolerable in Alzheimer's disease, not efficacy.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should note this trial is not yet reporting outcomes and is still enrolling. Once results are available, feasibility and tolerability data will inform whether larger efficacy trials of deep rTMS targeting the precuneus are warranted in Alzheimer's disease.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06597942). This is a study registration, not published results. Lead sponsor: University of California, Los Angeles. Recruitment status: RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 54 participants (ESTIMATED). Conditions: Alzheimer's Disease, Alzheimer Disease, Dementia Alzheimer Type, Mild Alzheimer's Disease, Moderate Alzheimer's Disease, Alzheimer's Disease (AD), Alzheimer's Dementia. Interventions: DEVICE: TMS; DEVICE: Transcranial Magnetic Stimulation Sham. Primary outcome measures: Completion Rate , From enrollment to the end of treatment after 9 weeks. Brief summary: The goal of this clinical trial is to learn if using large-coil (or "deep") repetitive transcranial magnetic stimulation (rTMS) targeting the precuneus and surrounding areas is feasible, tolerable, and potentially efficacious for memory in Alzheimer's Disease. Previous work studying rTMS in Alzheimer's is mixed, but recent work studying rTMS of the precuneus is encouraging for both its short-term and long-term effects. The main questions this study aims to answer are: * Is deep rTMS of the precuneus feasible and tolerable in Alzheimer's? * Are there signs of positive brain changes in response to deep rTMS? * Is deep rTMS potentially efficacious for memory in Alzheimer's? Researchers will compare active stimulation to placebo stimulation while obtaining memory testing and measurements of the brain (imaging, scalp electrode measurements, bloodwork) to see if active treatment works to treat Mild Cognitive Impairment (MCI) and mild-to-moderate dementia due to Alzheimer's disease. Participants will: * Engage with memory testing, brain scans, and bloodwork during a comprehensive assessment * Visit the clinic 3 times for 12 consolidated rTMS sessions, followed by 8 once weekly maintenance visits * Be offered a full open-label active treatment course after completing their treatment course if they are initially in the placebo group
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.